MarketVue®

On-demand commercial assessment reports

Built for early-stage disease market assessments and TPP evaluations — faster than consulting, more tailored than syndicated, and easier than doing it yourself.

REQUEST A DEMO

MarketVue®

YOUR COMMERCIAL INSIGHTS SOLUTION

Our insight rich and highly visual reports cover key market dynamics based on research from key opinion leader (KOL) interviews, physician surveys, and secondary data. REACH’s analysts distill critical market insights for any disease, so you don’t have to. You tell us the disease, and our team will create and deliver a MarketVue® in as little as 4 weeks.

Review sample content

MarketVue®

YOUR COMMERCIAL INSIGHTS SOLUTION

Our insight rich and highly visual reports cover key market dynamics based on research from key opinion leader (KOL) interviews, physician surveys, and secondary data. REACH’s analysts distill critical market insights for any disease, so you don’t have to. You tell us the disease, and our team will create and deliver a MarketVue® in as little as 4 weeks.

Review sample content

WHY MARKETVUE®

Less stressful than doing it yourself, faster than consulting, and more customized than syndicated — without sacrificing quality

COVERS ANY
DISEASE

MarketVue® reports can be created for any disease

FAST AND FRESH INSIGHTS

Assembled upon request; delivered in 4 weeks

SEMI-CUSTOM DELIVERABLE

Tailored to cover client questions and topics of interest

PRIMARY MARKET RESEARCH-DRIVEN

KOL insights and physician survey data complement secondary research

What our clients are saying about MarketVue

WHY MARKETVUE®

Less stressful than doing it yourself, faster than consulting, and more customized than syndicated — without sacrificing quality

COVERS ANY
DISEASE

MarketVue® reports can be created for any disease

FAST AND FRESH INSIGHTS

Assembled upon request; delivered in 4 weeks

SEMI-CUSTOM DELIVERABLE

Tailored to cover client questions and topics of interest

PRIMARY MARKET RESEARCH-DRIVEN

KOL insights and physician survey data complement secondary research

What our clients are saying about MarketVue

A LOOK INSIDE MARKETVUE®

Topics Covered

Disease Overview, Epidemiology, Current Treatment, Unmet Need, Pipeline Analysis, Value and Access

Geographic Scope

US plus EU5 (Spain, France, Italy, Germany, United Kingdom) epidemiology

Delivery Timeline

Delivered in as little as 4 weeks; immediate delivery available for published reports

REPORT STORE

A LOOK INSIDE MARKETVUE®

Topics Covered

Disease Overview, Epidemiology, Current Treatment, Unmet Need, Pipeline Analysis, Value and Access

Geographic Scope

US plus EU5 (Spain, France, Italy, Germany, United Kingdom) epidemiology

Delivery Timeline

Delivered in as little as 15 days; immediate delivery for published reports

DISEASES WE COVER

TRUSTED BY TOP-TIER PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES

What pushed me over the edge was that they have a nice way of presenting the findings in the end. Sometimes you get a wall of text. Their output was very clean and useful for putting into our slides. I’ve worked with a lot of vendors, and it can be pretty hit or miss. Some vendors can be good at executing, but REACH can be a thought partner. They can take what we’re saying and riff off of us, then come up with additional ideas and put them in front of us.

Kathleen Davenport

Senior Director, New Product Planning · Surface Oncology

It was great to see you at your market access pulse survey readout on Wednesday! The team’s feedback has been consistently very positive with the product quality, Melissa’s expertise, and the process getting the research completed on time. I’m so glad that [name] has you as an obvious go-to-choice for ad hoc requests for [our product].

Sr. Manager, Commercial Analytics

For us, MarketVue® is very valuable to get fast reports and at the right level of detail. We were originally supposed to develop disease strategies but then we had a reorganization and resources were constrained. REACH is a great help to us.

Konstanze Binder

Principal, Global Asset Maximization · LEO Pharma

I need something beyond what I can do for myself with Google and without paying an extraordinary amount of money… MarketVue® goes even further — it’s not your typical syndicated report. It was very collaborative. REACH operates with the best aspects of primary research but then benefits like speed of syndicated reports.

Tony Russell

Director, Commercial Development · Pfizer

With MarketVue® reports, you can get 80-90% of output for 10% of the cost [of custom consulting] — this is great, especially for small clients like us whose budgets are tight, and we don’t have a ton of FTEs. I’m a team of 1. I can’t blow my whole budget on a single question.

Joe Pirrello

Executive Director, Business Development · Astria Therapeutics

Regarding the [rare disease] development program related to our project before the break, I don’t recall if I ever relayed the message – folks were very complimentary of the supportive market research, so THANK YOU very much for a very successful and timely engagement. Let’s stay in touch over the coming weeks on any imminent projects that may materialize on our end.

Director, New Product Commercialization

Before even getting to the MarketVue® product, the process is a huge plus for them. The fact that we can get a tailored report with essentially a proprietary set of questions at that price range with that level of engagement with the team is hugely valuable and gives us a lot of trust with what we receive. MarketVue® is really high quality in general and comparable to much more expensive reports where you get a 100-page report — in terms of value for the amount we use it, it is comparable to much, much more expensive research… They’re really good at highlighting what is most relevant.

Julia Chornak

Senior Manager, Market Insights · Chinook Therapeutics

BTW – I wanted to tell you that the chatter with the [rapid insights] work you just delivered within our NPC team is that you killed it. So, I anticipate you will be our go to for much more work like this in the future.

Director, Pipeline/New Product Commercialization

REACH reports give you the ability to tailor the research a little bit more. I work in rare disease where [syndicated reports] just don’t exist and if they do, they’re not built out. For folks like myself, there is limited ability to use those off-the-shelf reports since they’re focused on mass market. I value the REACH team’s ability and willingness to answer follow up questions, dive in around specific topics, push back on the report, and think critically with us around the implications of the findings… I eventually asked them to synthesize all of our email back/forth into a separate report because I thought it was so useful and thoughtful.

Joe Pirrello

Executive Director, Business Development · Astria Therapeutics

What pushed me over the edge was that they have a nice way of presenting the findings in the end. Sometimes you get a wall of text. Their output was very clean and useful for putting into our slides. I’ve worked with a lot of vendors, and it can be pretty hit or miss. Some vendors can be good at executing, but REACH can be a thought partner. They can take what we’re saying and riff off of us, then come up with additional ideas and put them in front of us.

Kathleen Davenport

Senior Director, New Product Planning · Surface Oncology

It was great to see you at your market access pulse survey readout on Wednesday! The team’s feedback has been consistently very positive with the product quality, Melissa’s expertise, and the process getting the research completed on time. I’m so glad that [name] has you as an obvious go-to-choice for ad hoc requests for [our product].

Sr. Manager, Commercial Analytics